They demonstrated that systemic injection of cell‐penetrating C‐MYC and Gp130 peptides could prevent pancreatic cancer growth and induce the anti‐tumour immune response and indirectly producing anti‐tumour effects through anti‐tumour immunity response. Here, MYC is linked to neoplasm.